Clin2
NCT07449910Possibly a fitNot yet recruiting

Baricitinib after clot removal for stroke

Acute Ichemic StrokeAnterior Cerebral Artery StrokeBaricitinib

Part of Brain & nervous system, Heart & circulation clinical trials.

This study tests whether the drug baricitinib, given after a mechanical clot-removal procedure, helps improve recovery in people who had a stroke from a large clot in the front of the brain. The drug may reduce inflammation and protect brain tissue.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2/Phase 3
Enrollment
750 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must be 18 years or older.
  • You had a stroke from a large clot in the front part of the brain, confirmed by imaging, and you can be enrolled within 24 hours of the stroke starting.
  • You had a mechanical thrombectomy (clot removal) that was successful (blood flow restored).
  • You must not have a bleeding condition or be on blood thinners that increase bleeding risk.
  • You cannot be pregnant, breastfeeding, or have a history of hepatitis or tuberculosis.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07509645Recruiting· Phase 3
Testing a new drug with clot removal for severe back-of-the-brain stroke

This trial checks if adding an interleukin-6 receptor inhibitor (a drug that reduces inflammation) to standard emergency clot removal can improve recovery for people with a severe stroke affecting the back part of the brain (posterior circulation). It is for patients who need urgent treatment within 24 hours of symptom onset.

Suzhou, Anhui
NCT06439615Not yet recruiting· Phase 2
Baricitinib for lung injury after sudden brain bleed

This study tests whether a medication called baricitinib can help protect the lungs in people who have had a sudden bleed around the brain. Baricitinib works by calming inflammation, which might reduce lung injury after the bleeding.

NCT06065046Recruiting· Phase 2
Baricitinib for traumatic brain bleeding

This trial tests if baricitinib, an anti-inflammatory drug, can help people with bleeding in the brain from a head injury. It is for adults with moderate to severe traumatic brain injury who are not immediately having surgery.

Xi'an, Shaanxi
NCT06548802Recruiting· Phase 1/Phase 2
Baricitinib for lung injury after brain bleed

This trial tests a pill called baricitinib to see if it helps people recover from lung injury after a brain bleed. It is for patients who need a breathing machine due to ARDS that started within a week of the bleed.

Tianjin, Tianjin Municipality
NCT07357649Not yet recruiting· Phase 4
Study of baricitinib on blood clotting in rheumatoid arthritis

This trial tests if baricitinib, a medication for rheumatoid arthritis, can improve blood clotting issues that some patients with active RA face. It is for adults whose RA is not well-controlled by standard treatments.

Tanta
NCT06373042Not yet recruiting· Phase 2/Phase 3
Tirofiban after successful stroke clot removal

This trial tests if adding a blood thinner called tirofiban after successful clot removal can improve recovery in people with severe stroke. It is for patients who had a large blockage and are treated within 24 hours of symptoms starting.

Hear when a new Acute Ichemic Stroke trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.